Document |
Document Title |
WO/2012/109280A2 |
The present invention provides antibodies that preferentially bind to an ApoE(1-272) fragment relative to ApoE(1-299). These antibodies serve to reduce the toxicity of this fragment and find use in treatment and prophylaxis of a variety ...
|
WO/2012/105471A1 |
The purpose of the present invention is to provide, as a method for immobilizing a protein molecule, a protein immobilizing method and means that enables control of the orientation of a molecule to be immobilized, that does not require c...
|
WO/2012/093162A1 |
The present invention relates to a biosensor for detecting the presence and/or the enzymatic activity of at least one protease, which corresponds to a biosensor comprising a substrate functionalized with organic compounds comprising at l...
|
WO/2012/093706A1 |
The purpose of the present invention is to discover a method to obtain an antibody for hydrophobic peptides, which can be used for general purposes easily and with great reliability. This method for preparing an antigen is characterized ...
|
WO/2012/091110A1 |
The present invention provides, as a modified tamavidin 2, a modified biotin-binding protein which is characterized by being obtained by substituting the 115th asparagine residue in SEQ ID NO: 2 with cysteine in a protein that comprises ...
|
WO/2012/083425A1 |
The present invention relates to immunoglobulin (Ig)-binding proteins with alkali- resistance properties. In one embodiment, the present invention provides for a variant of an Ig-binding protein, the variant comprising the Ig-binding pro...
|
WO/2012/086660A1 |
Provided are a support for affinity chromatography, which has excellent alkali resistance, and a method for isolating immunoglobulin. The support for affinity chromatography is a support, onto which a protein ligand represented by genera...
|
WO/2012/083424A1 |
The present invention relates to anchor peptides for linking a ligand molecule to a solid support. The anchor peptide includes an amino acid motif having at least one neutral polar residue and at least one basic polar residue. In one asp...
|
WO/2012/086837A1 |
Provided is a method for producing an immobilization medium for temperature-responsive protein A, which is protein A mutated in a manner so that the affinity to an antibody changes dependent on temperature. The temperature-responsive pro...
|
WO/2012/085080A1 |
It is herein disclosed a new methodology to detect an enzyme, in particular a protease (i.e. a protein capable of hydrolyzing peptide ligands). The determination is based on the activation of colloidal gold nanoparticles with catalytic p...
|
WO/2012/078559A2 |
The present invention relates to the ability to regulate any protein of interest in living systems with small molecules. In particular, the present invention relates to the discovery that appending a hydrophobic moiety to the surface of ...
|
WO/2012/077080A1 |
This invention relates generally to the fields of separation and conversion technologies, and more particularly to materials for use in tangential-flow filtration techniques. The tangential- flow materials are useful in a wide range of s...
|
WO/2012/077950A2 |
The present invention relates to a hyaluronic acid-protein conjugate in which a hyaluronic acid-aldehyde derivative, in which derivative an aldehyde group is introduced to a hyaluronic acid or the salts thereof, is bound to N-terminal of...
|
WO/2012/065362A1 |
The present invention provides a novel myomegalin isoform - myomegalin variant 8 (MMG8). The myomegalin variant 8 regulates microtubule organization at the Golgi apparatus, protein modification, secretion and trafficking, and cell prolif...
|
WO/2012/066420A1 |
This invention relates to, inter alia, an isolated lipidated polypeptide including a lipid moiety at the N-terminus and a plurality of epitopes, and methods of making and using the polypeptide.
|
WO/2012/055205A1 |
Provided is a PEGylated recombinant consensus interferon variant conjugate, in which the aldehyde-activated polyethylene glycol with the molecular weight in the range of 10KD-40KD is attached to the amino terminal of the recombinant cons...
|
WO/2012/055509A1 |
The invention relates to a method for homogeneous solution phase peptide synthesis (HSPPS) of a N-terminal peptide fragment PEP-N and a C-terminal peptide fragment C-PEP, with C- PEP carrying a specific diketopiperazine (DKP) comprising ...
|
WO/2012/055030A1 |
The present invention is directed to Clostridium difficile toxin-specific antibodies, compositions, and uses thereof. The anti-toxin antibodies may be specific for either TcdA or TcdB. The invention also includes methods of treating a Cl...
|
WO/2012/054901A1 |
Disclosed are compositions and methods for identifying and preferably quantifying single antigens/molecules in tissue sections and other cell preparations. The methods make use of specific antibodies or aptomers linked with beads or othe...
|
WO/2012/051516A1 |
The present invention in one embodiment uses detection of isoforms of CAP37 in a fluid as an early detection marker for a chronic inflammatory- associated disease. Chronic inflammatory-related diseases may include, for example, atheroscl...
|
WO/2012/048877A1 |
The present invention concerns a new dimedon derivative and a method for the purification of PNA and peptide oligomers.
|
WO/2012/050822A1 |
Methods and associated compositions of matter (e.g., kits, cell lines, etc.) for screening compounds that bind to macrophase mannose receptor (MMR). Compounds identified by these methods and drug conjugates that includes these compounds ...
|
WO/2012/051425A1 |
The invention provides methods for permanently or reversibly immobilizing molecules such as proteins, peptides, and polynucleotides on insoluble substrates such as silica, glass, and polymer beads functionalized with thioester groups. Th...
|
WO/2011/146518A9 |
The present invention relates to modified forms of C-peptide, and methods for their use. In one aspect, the modified forms of C-peptide comprise PEGylated C-peptide derivatives comprising at least one PEG group attached to the N-terminus...
|
WO/2012/043634A1 |
Provided is an antibody, which binds to the subtype EP4 of human PGE2 receptor and inhibits the function of EP4, or a functional fragment thereof. Also provided is a drug comprising said antibody or a functional fragment thereof. Mice we...
|
WO/2012/042062A2 |
The invention relates to novel marker sequences for multiple sclerosis and to the use thereof in diagnosis as well as to a method for screening potential active ingredients for multiple sclerosis diseases using said marker sequences. The...
|
WO/2012/043533A1 |
The purpose of the present invention is to provide a novel antihuman CCR7 antibody which is useful as a therapeutic agent for tissue fibrosis or cancer, a medicinal composition which comprises the antihuman CCR7 antibody, and so on. Prov...
|
WO/2012/040825A1 |
Disclosed is a recombinant polypeptide for facilitating membrane fusion. The recombinant polypeptide having a sequence with at least 80% sequence identity with the ectodomain of p14 fusion-associated small transmembrane (FAST) protein an...
|
WO/2012/031518A1 |
Disclosed are PEGylated modifications of Exendin-4 analogs and uses thereof. In particular, disclosed are PEGylated modifications of Exendin-4 analogs as shown in formula (I), i.e., PEG-M-X-(Ex-4), or pharmaceutically acceptable salts th...
|
WO/2012/029202A1 |
The object of the present invention is to provide a method for increasing an amount of streptavidin to be immobilized on the self-assembled monolayer and a sensor which comprises streptavidin immobilized with the method. Immobilizing str...
|
WO/2012/026887A1 |
The present invention generally relates to various peptides and particles, for example, for use in screening of particle- or bead-based peptide libraries. In one aspect, the present invention is generally directed to articles including p...
|
WO/2012/024784A1 |
A peptide comprising the amino acid sequence, X1X2RX3DX4X5 X6 X7 is provided, as well as a biomaterial comprising the peptide for use to treat conditions resulting from cell death or apoptosis.
|
WO/2012/026541A1 |
Disclosed are: (a) a step where, on a micro-engraved plate that consists of microscopic grooves that have a specific mouth shape, nucleic acids and an acellular protein synthesis system are prepared within said microscopic grooves; (b) a...
|
WO/2012/024613A1 |
The synergistic biomolecule-polymer conjugates are the long-acting, in vivo controlled continuous-release and hybrid synergy systems of biomolecules that provide increased biological activities and enhanced pharmacological properties for...
|
WO/2012/024452A2 |
Modified relaxin polypeptides and their uses thereof are provided.
|
WO/2012/020124A1 |
The method and constructs disclosed and claimed herein allow to control peptide conformation by modulation of the peptide lipidation pattern, spacer and liposome composition, or via co-administration with small molecules. Accordingly, th...
|
WO/2012/009953A1 |
Provided are compositions for controlled release of biomolecules, which comprise conjugates of polymers and biomolecules conjugated through non-covalent interactions. Also provided are methods for controlled release of biomolecules and t...
|
WO/2012/006395A1 |
Multilayer films comprise polypeptide epitopes from RSV. The multilayer films are capable of eliciting an immune response in a host upon administration to the host. The multilayer films include at least one designed peptide that includes...
|
WO/2003/085121A9 |
|
WO/2011/161017A1 |
A separation medium is provided, comprising at least one megalin polypeptide and/or at least one cubilin polypeptide immobilized on a support. Also provided are devices comprising the separation medium, as well as methods and uses employ...
|
WO/2011/155536A1 |
The object is to provide a support for enzyme immobilization, which is usable for immobilizing enzymes of various molecular sizes and also usable, due to the modification of the surface silanol group in porous silica particles, for immob...
|
WO/2011/150671A1 |
A magnetic composite, preparation method and use thereof are provided. The magnetic composite is multilayer core-shell architecture with Fe3O4 nanoparticle cores and an A-b-poly(ethylene glycol)-b-poly(glycerol mono(meth)acrylate) triblo...
|
WO/2011/148952A1 |
Disclosed is a peptide which is characterized by comprising an amino acid sequence that is represented by (X1-3)-C-(X8-10)-C-(X1-3) (wherein each X independently represents an arbitrary amino acid residue other than cysteine and C repres...
|
WO/2011/143562A2 |
Proteins that bind IL-1α and IL-1β are described along with their use in compositions and methods for treating, preventing, and diagnosing IL-1 -related disorders and for detecting IL-1α and IL-1β in cells, tissues, samples, and comp...
|
WO/2011/140590A1 |
A method of adapting a synthetic substrate for immobilisation of a target molecule thereon.
|
WO/2011/138757A1 |
The present invention relates to the use of a peptide consisting of 5 to 30 amino acid residues comprising an amino acid sequence selected from LLADTTHHRPWT (SEQ ID NO: 1), SPGLSLVSHMQT (SEQ ID NO: 2), and the sequences presenting at lea...
|
WO/2011/138641A1 |
A construct comprising a Ni and/or Au substrate provided of hexa-histidine-tagged protein A or G suitable for building a layer of antibodies featuring an enhanced antigen binding ability, wherein said hexa-histidine- tagged protein A or ...
|
WO/2011/127585A1 |
The present invention relates to a method for diagnosis of cancer and for monitoring the progression of cancer and/or the therapeutic efficacy of an anti-cancer treatment in a sample of a subject by detecting oncogenic and cancer related...
|
WO/2011/118599A1 |
Provided are a filler for affinity chromatography which is highly tolerant to alkalis, and a method for isolating immunoglobulin. The filler for affinity chromatography is a filler wherein a protein represented by general formula (1) is ...
|
WO/2011/109298A2 |
DLL4 binding proteins are described herein, including antibodies, CDR-grafted antibodies, humanized antibodies, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL...
|